Tyra Biosciences Reports Unregistered Equity Sales
Ticker: TYRA · Form: 8-K · Filed: Oct 18, 2024 · CIK: 1863127
| Field | Detail |
|---|---|
| Company | Tyra Biosciences, Inc. (TYRA) |
| Form Type | 8-K |
| Filed Date | Oct 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: unregistered-sales, equity-securities, capital-structure
TL;DR
Tyra Biosciences sold unregistered equity, potentially diluting shares.
AI Summary
On October 18, 2024, Tyra Biosciences, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing indicates that the company engaged in transactions involving equity securities that were not registered under the Securities Act of 1933.
Why It Matters
This filing signals potential dilution or changes in the company's capital structure due to unregistered equity transactions, which may impact existing shareholders.
Risk Assessment
Risk Level: medium — Unregistered sales can sometimes indicate financial distress or a need for capital, and may lead to dilution for existing shareholders.
Key Players & Entities
- Tyra Biosciences, Inc. (company) — Registrant
- October 18, 2024 (date) — Date of Report
- 2656 State Street, Carlsbad, California 92008 (address) — Principal Executive Offices
FAQ
What specific type of equity securities were sold unregistered?
The filing does not specify the exact type of equity securities sold unregistered, only that unregistered sales of equity securities occurred.
Were these sales part of a private placement or other exemption from registration?
The filing indicates 'Unregistered Sales of Equity Securities' but does not detail the specific exemption or nature of the sale.
What was the total dollar amount of these unregistered equity sales?
The filing does not disclose the dollar amount of the unregistered equity sales.
Who were the purchasers of these unregistered equity securities?
The filing does not identify the purchasers of the unregistered equity securities.
Does this filing relate to any recent financing rounds or capital raises?
While the filing reports unregistered sales of equity, it does not explicitly state if it is part of a broader financing round or capital raise.
Filing Stats: 872 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2024-10-18 16:23:53
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share TYRA Nasdaq Global Select
- $0.001 — change Warrant has an exercise price of $0.001 per share of Common Stock, is immediate
Filing Documents
- d814860d8k.htm (8-K) — 27KB
- d814860dex41.htm (EX-4.1) — 71KB
- 0001193125-24-239650.txt ( ) — 241KB
- tyra-20241018.xsd (EX-101.SCH) — 3KB
- tyra-20241018_lab.xml (EX-101.LAB) — 18KB
- tyra-20241018_pre.xml (EX-101.PRE) — 11KB
- d814860d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Exchange Warrant 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TYRA BIOSCIENCES, INC. Date: October 18, 2024 By: /s/ Ali Fawaz Ali Fawaz General Counsel and Secretary